IRVING, TX / ACCESSWIRE /5, 2024 / OnAsset Intelligence is thrilled to announce a collaboration with Phaslo Pathology in creating solutions tailored to solve the complexities in the pathology industry ...

Healius will be in a “material net cash position’’ following the sale of its Lumus Imaging division for $965m, and will ...

The sale represents a total consideration of $965 million with cash proceeds estimated to be around $835 million. The sale of Lumus which accounts for almost half of the fiscal 2024 group operating ...

Shares in the pathology company jumped 6 per cent after it achieved a robust price for Lumus, which does MRI, X-rays and CT ...

Healius is set to become debt-free after selling its radiology business, Lumus Imaging, for $965 million, exceeding analyst ...

Previously, Galmed reported results from the Open-Label part of its Phase 3 NASH study, which demonstrated that treatment with Aramchol 300mg BID resulted in a high rate of subjects with histological ...

GRM and HistoWiz expand their partnership, with HistoWiz now using GRM's pathology storage services for blocks and slides.

Fulgent Genetics is transforming into a healthcare company with a focus on oncology, presenting a promising opportunity. Read ...

Healius Ltd. agreed to sell its Lumus imaging unit to a private equity group for A$965 million ($657 million), as the loss-making Australian medical diagnostics company focuses on its pathology ...

Katharine Mitropoulos, an author and the founder of Set Sail Press LLC, hosted a book launch event for her second book, ...

The jury is currently out on whether pathology giant Healius will be better off without its Lumus imaging business.

Healius shareholders were surprised on Monday about how much Affinity Equity Partners was prepared to pay for its Lumus Imaging business with the stock rallying more than 7 per cent on the news.